GlassScriptPhysician profile
Adrienne M Camesas
NPI 1780799148
$4,445.54
in general payments reported to CMS, 2019-2025
43 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $173 · 2021: $514 · 2022: $399 · 2023: $847 · 2024: $1,106 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.23 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $376.41 | 2019-2024 | |
| Amgen INC. | $353.24 | 2020-2025 | Repatha, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $318.17 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $296.53 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $294.79 | 2023-2025 | Watchman Flx, Watchman Access System |
| Abbott Laboratories | $259.54 | 2023-2024 | Amplatzer Amulet, Mitraclip |
| Daiichi Sankyo INC. | $204.89 | 2020-2024 | Injectafer |
| Novo Nordisk INC | $145.76 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $136.42 | 2019-2021 | |
| Philips North America LLC | $135.52 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Amneal Pharmaceuticals LLC | $96.60 | 2023-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.17 | 2021-2025 | Xifaxan |
| Pfizer INC. | $90.96 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.71 | 2021-2024 | Lifevest |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Camesas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.